Biologics 2024

13 - 15 March 2024 | London, UK

Europe's premier platform for key opinion leaders to discuss the latest innovations & technological advancements in biologics discovery & development.

Presentation Speaker
Overview Proteins & Antibodies Peptides Oligonucleotides Sustainability in Biologics

Explore Biologics 2024: Unlocking Future Insights in Biologics Research

Join leaders, experts and researchers at Biologics 2024, connecting pharmaceutical & biotech representatives as well as academia for high-level discussions on the latest innovations in biologics discovery & development. Biologics 2024 features the co-location of Oxford Global’s flagship 17th Annual Proteins & Antibodies Congress, 11th Annual Peptides Congress, 3rd Annual Oligonucleotides Congress and 2nd Annual Sustainability in Biologics Congress. New to 2024 is the introduction of the Innovation & Collaboration track showcasing emerging biotechs & academic spin offs entering the market.

17th Annual Proteins & Antibodies Congress

Join forward-thinking scientific experts at our annual Proteins & Antibodies congress, addressing critical strategies & latest technological advancements in antibody engineering, the successful implementation of AI/ML technologies as well as the latest case studies and best practices in the development of next gen multi-specific therapeutics.

  • New to 2024! Gain invaluable insights into ADC design, bioconjugation, validation & optimisation to enhance their therapeutic potential. Presentations will cover linker / payload technologies to achieve better therapeutic index and immunostimulatory ADCs
  • Discuss the latest innovations & new approaches in antibody discovery & engineering. Hear about innovative engineering approaches, developing new in vitro display technologies and humanized animal models
  • Take a deep dive into nextgen multi-specifics & cell engagers through engaging presentations on combination therapies, identifying & validating new targets and conditional activation of biologics

Agenda at a Glance


Day One & Two | Track 1: Antibody Discovery & Engineering

Day One & Two | Track 2: ADC Design, Validation & Optimisation to Enhance Their Therapeutic Potential

Day One & Two | Track 3: Emerging Analytic Techniques, Characterisation & Quality Control Systems

Day Three | Track 1: AI/ML-Guided Protein & Antibody Engineering

Day Three | Track 2: NextGen Multi-Specifics, Cell Engagers & Other New Modalities

11th Annual Peptides Congress

Our annual event will bring together leading experts in peptide chemistry & therapeutic development. With the latest technological advancements pushing the industry forward, join us in London to network, debate and discuss the pressing challenges & future opportunities.

  • Join key opinion leaders discussing AI-guided peptide chemistry, computational approaches and the utilisation of peptides across various application areas. Presentations will cover AI/ML implementation case studies, advanced formulation strategies and cosmetic peptides
  • Stay at the forefront of peptide therapeutics research & development with hearing about novel targeted delivery methods, advances in peptide design and characterisation updates
  • Take part in our interactive sessions including a panel discussion exploring peptide drug lead optimisation and candidate selection

Agenda at a Glance


Day One & Two | Track 4: AI-Guided Peptide Chemistry, Computational Approaches & Case Studies from Application Areas

Day Three | Track 3: Peptide Therapeutics, Targeted Delivery & Development

3rd Annual Oligonucleotides Congress

Join key opinion leaders at this annual event, bringing about a new era of innovation in this field. Presentations will be covering computational approaches, methods & tools to oligonucleotide CMC as well as analytical control strategies for oligos. 

  • Discuss the latest therapeutic development success stories with thought-leaders presenting on immunogenicity considerations, progress to clinical trials and RNA targeting
  • Explore the most exciting trends in oligo discovery, from novel engineering strategies to optimal design strategies
  • Stay up-to-date with current advances in oligonucleotide delivery with presentations on nanoparticle technologies and conjugation strategies

Agenda at a Glance


Day One & Two | Track 5: Oligonucleotide CMC & Analytical Development

Day Three | Track 4: Therapeutic Development & Discovery of Oligonucleotides

2nd Annual Sustainable Chemistry Congress

Our one-day Sustainability in Biologics Congress addresses an important and expanding area, providing insights into driving sustainable innovation across biologics research & development.

  • Take a deep dive into peptide & oligonucleotide green chemistry & innovations in manufacturing. Hear thought-leaders achieving sustainability in synthesis, advanced technologies and high-throughput purification methods
  • Express your thoughts on the future of solvent recovery systems and implementation of new sustainable manufacturing technologies
  • Explore the latest methodology in sustainable drug formulations including the usage of green and renewable APIs

Agenda at a Glance


Day Two Focus Session: Moving Towards Green Chemistry & Green Innovations In Manufacturing

What to Expect

650

leading pharma, biotech & academic delegates

30
hours of presentations, discussions & interactive content
13
hours of networking breaks, including speed networking & refreshments
320
hours of pre-arranged 1-2-1 meetings, facilitating business growth
Interactive Presentations
Exhibition Hall
Networking Drinks
Poster Display
Event App Swapcard

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 120 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Companies Represented Include

Meet Our Expert Speakers

Biologics 2024 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Below are some of our featured speakers:

Amita Datta-Mannan
Associate Vice President, Exploratory Medicine and Pharmacology,
Eli Lilly & Company
Erik Vernet
Senior Director - External Partnerships,
Novo Nordisk A/S
Fernando Albericio
Research Professor,
University of KwaZulu-Natal
Rebecca Croasdale-Wood
Director Augmented Biologics Discovery and Design,
AstraZeneca
Soraya Hölper
Project Lead,
Sanofi
Thierry Besson
Senior Scientist II,
Novartis

All Speakers

Adrian Torres
Head of R&D,
Aptadel Therapeutics
Alastair Lawson
Fellow,
og.com
Alethea Tabor
Professor of Chemical Biology,
UCL
Alex Zwetsloot
Scientific Investigator,
GSK
Andreas Bernkop-Schnürch
Professor,
Innsbruck University
Andrew Livingston
Professor,
Queen Mary University of London
Annemieke Madder
Full Professor,
Ghent University
Arwyn Jones
Professor of Membrane Traffic and Drug Delivery,
Cardiff University
Bryce Nelson
Antibody Engineering Lead,
Orion Pharma
Carly Dix
Associate Director,
Astrazeneca
Catalin Nistor
Director Pharmaceutical Research & Early Dev,
Camurus AB
Celine Amara
DMPK Project Expert,
Sanofi
Christian Rohlff
Chief Executive Officer,
Oxford Biotherapeutics
Christian Reichen
Director,
Molecular Partners AG
Christopher Hart
Chief Executive Officer and Co-Founder,
Creyon Bio
Cleo Kontoravdi
Professor of Biological Systems Engineering,
Imperial College London
Darko Skegro
Associate Director- Group Head,
Novartis
david evans
Head Drug Discovery,
Sirnaomics
Dimitri Bieli
EVP Molecular Biology,
Mabylon AG
Emma Jenkins
Director,
Alchemab Therapeutics
Filippo Sladojevich
Senior Principal Scientist,
Hoffmann-La Roche
Hélène Aerts
Early Translational Medecine Representative,
Servier
Hilmar Ebersbach
Senior Vice President,
Immunos Therapeutics
Horst Bierau
Associate Director - Head CMC Science & Intelligence,
Merck KgaA
Ian Hamley
Diamond Professor of Physical Chemistry,
University of Reading
Immanuel Lerner
Chief Executive Officer,
Pepticom
Jacob Kofoed
Principal Scientist,
Novo Nordisk
Jitka Riedl
Associate Principal Scientist,
Bicycle Therapeutics
Joel Richard
Chief Development Officer,
Enterome
Jonathan Hall
Professor,
ETH Zurich
Lars Nieba
Chief Executive Officer,
Engimmune Therapeutics AG
Louis Diorazio
Senior Principal Scientist,
AstraZeneca
Lukasz Kielpinski
Senior Principle Scientist,
Roche
Mahendra Deonarain
Chief Executive Officer,
Antikor
Mark Bushell
Director of Technology Development,
maxion.co.uk
Martin Münzel
Scientific Director,
Novo Nordisk
Massimo Domenico Sammito
Associate Principal Scientist,
AstraZeneca
Mattias Levin
Director, Antibody Technology Innovation,
Alligator Bioscience
Michael Gutknecht
Pricipal Scientist II,
Novartis Pharma AG
Nesrine Chakroun
Associate Director,
Merus NV
Oliver Hartley
Vice President Drug Discovery,
Orion Biotechnology
Patrick Schindler
Principle Scientist,
Novartis
Paul Dalby
Professor,
University College London
Poonam Vaghela
Scientist,
Scancell
Rajesh Sundaresan
Scientific Leader,
GSK
Rajika Perera
Chief Executive Officer,
Poseidon LLC
Robert Boyd
Vice President R&D,
Elasmogen
Rodrigo Ochoa
Senior Scientist,
Novo Nordisk
Samuel Pine
Global Head of Bioanalysis & Immunogenicity, Drug Metabolism and Pharmacokinetics,
Sanofi
Sandor Batkai
Head of Medical Research and Intelligence,
Cardior Pharmaceuticals GmbH
Sandra Prior
Principal Scientist,
Mhra
Shirley Peters
Senior Group Leader,
UCB
Shwana Braim
Lecturer,
Nottingham Trent University
Silvia Crescioli
Independent Consultant,
The Antibody Society
Simon Chell
Vice President, Biologics Engineering,
AstraZeneca
Simone Mester
CEO,
Authera AS
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Talip U
Sr. Director,
AstraZeneca
Thierry Monney
Senior Principal Scientist,
Ichnos Glenmark Innovation
Thomas Nittoli
Senior Director,
Regeneron
Tomas Leek
Director,
AstraZeneca
Torleif Gjoelberg
Chief Scientific Officer,
Authera AS
Trevor Wattam
Scientific Leader,
Glaxosmithkline
Ulrike Philippar
Vice President Oncology,
Johnson & Johnson
Vikash Reebye
Senior Principal Scientist,
MiNA Therapeutics
Vladimir Gligorijevic
Senior Director of AI/ML,
Genentech
Will Lewis
Director,
GSK
Yi Yang
Principal Scientist,
Ferring Pharmaceuticals A/S
Yingnan Zhang
Senior Principal Scientific Manager,
Genentech

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

Recombinant vs. Chemical Peptide Synthesis: A Question of Sustainability

Recombinant and chemical peptide synthesis methods both have use cases in modern peptide production. Today the industry is looking to sustainable approaches to both.

The Vital Role of Sustainable Peptide Synthesis in Advancing Drug Development

Sustainable peptide synthesis refers to the development and implementation of methods that minimize the environmental impact of peptide manufacturing while maintaining high efficiency and yield.

Mechanochemical Synthesis as a Solvent-Free Peptide Synthesis Method

Mechanochemical synthesis could unlock new pathways for obtaining peptides in a sustainable and ecologically friendly way.

Plan Your Visit

Novotel London West

1 Shortlands,
Hammersmith International Ctre,
London, W6 8DR

Just minutes from three of London's main tube lines (Piccadilly, District and Hammersmith & City) and located in the heart of Hammersmith; Novotel London West is ideally located for trips to Westfield London, Harrods & Kensington High Street. Also conveniently located to Heathrow Airport with excellent road and rail links to the rest of the UK. This large and modern hotel offers on-site parking (chargeable), fitness suite and complimentary Wi-Fi throughout.

By Air

London Heathrow Airport - Novotel London West is accessible from Heathrow via the Underground on the Piccadilly Line – fares cost around £5 into Central London. A taxi from the airport will take approximately 20 minutes and will cost around £30 - £40.

London Gatwick Airport - The Gatwick Express runs every 15 mins - take it to Victoria station, and then get the District line to Hammersmith (about 15 mins). A taxi from the airport will take around 60 mins and cost between £65 - £80.

By Underground & Bus

Hammersmith Underground Station is adjacent to the hotel (3 minutes walk) with access to the Piccadilly, District and Hammersmith & City Lines. When exiting Hammersmith station, turn right and walk across the bus station. Cross over the roads using the island and keep on the right-hand side of Hammersmith Road. Continuing walking for 2 mins, and the hotel is accessible via stone steps.

For buses in central London, take route numbers 9 and 10. The main coach station (London Hammersmith) is 3 minutes walk away.

By Rail

The closest National Rail train station is Kensington Olympia (20 minutes walk).

By Car

Leave the A4 at the Hammersmith turning and proceed along Hammersmith Bridge Road to the large roundabout underneath the flyover. Take the fifth exit off the roundabout. Then turn left into Shortlands - the main hotel entrance and parking will be on your left-hand side.

Parking

Novotel London West offers over 240 on-site car parking spaces (charged per hour for residents parking). For further information including a map and full directions, please visit: www.novotel.com/gb/hotel-0737-novotel-london-west/index.shtml

We have now SOLD OUT of discounted rooms.

If you wish to stay at the venue you can book directly on their website : Novotel London West - Book here

 

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Biologics 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch